tbuckley/cabot-search huggingface dataset:
[123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics
Authors: E Klemm, F Grünwald, S Kasper, C Menzel, K Broich, P Danos, K Reichmann, C Krappel, O Rieker, B Briele, A L Hotze, H J Möller, H J Biersack
Journal: American Journal of Psychiatry (1996)

The purpose of this study was to compare the binding of various typical and atypical neuroleptics to striatal D2 dopamine receptors in schizophrenic patients.Fifty-six inpatients with schizophrenia, including 14 with schizoaffective disorder and one with schizophreniform disorder, were evaluated. Fourteen patients were neuroleptic free. Single photon emission computed tomography (SPECT) was performed 90 minutes after intravenous injection of [123I]benzamide ([123I]IBZM). Subsequent semiquantitative analysis of D2 receptor binding was done with the use of the basal ganglia (striatum)/frontal cortex (BG/FC) ratio of activity. Clinical symptoms were rated with the Positive and Negative Syndrome Scale and the Hamilton Depression Rating Scale.The BG/FC ratios in patients taking typical neuroleptics were significantly lower than those in the neuroleptic-free subjects but not lower than those in the patients taking atypical neuroleptics (clozapine, remoxipride). For atypical antipsychotics, a dose-dependent relationship with striatal D2 receptor binding could not be demonstrated. BG/FC ratios were not significantly correlated with clinical symptoms or with duration of illness.The results indicate that [123I]IBZM SPECT is useful for semiquantitative imaging of striatal D2 dopamine receptors and for estimating their blockade by neuroleptics. Thus, it may improve drug monitoring in psychiatric patients. Furthermore, the findings suggest a complex relationship between the antipsychotic effect of atypical neuroleptics and D2 receptor blockade.
Right and Left Ventricular Function and Mass in Male Elite Master Athletes
Authors: Philipp Bohm, Günther Schneider, Lutz Linneweber, Axel Rentzsch, Nadine Krämer, Hashim Abdul-Khaliq, Wilfried Kindermann, Tim Meyer, Jürgen Scharhag
Journal: Circulation (2016)

It is under debate whether the cumulative effects of intensive endurance exercise induce chronic cardiac damage, mainly involving the right heart. The aim of this study was to examine the cardiac structure and function in long-term elite master endurance athletes with special focus on the right ventricle by contrast-enhanced cardiovascular magnetic resonance.Thirty-three healthy white competitive elite male master endurance athletes (age range, 30-60 years) with a training history of 29±8 years, and 33 white control subjects pair-matched for age, height, and weight underwent cardiopulmonary exercise testing, echocardiography including tissue-Doppler imaging and speckle tracking, and cardiovascular magnetic resonance. Indexed left ventricular mass and right ventricular mass (left ventricular mass/body surface area, 96±13 and 62±10 g/m(2); P<0.001; right ventricular mass/body surface area, 36±7 and 24±5 g/m(2); P<0.001) and indexed left ventricular end-diastolic volume and right ventricular end-diastolic volume (left ventricular end-diastolic volume/body surface area, 104±13 and 69±18 mL/m(2); P<0.001; right ventricular end-diastolic volume/body surface area, 110±22 and 66±16 mL/m(2); P<0.001) were significantly increased in athletes in comparison with control subjects. Right ventricular ejection fraction did not differ between athletes and control subjects (52±8 and 54±6%; P=0.26). Pathological late enhancement was detected in 1 athlete. No correlations were found for left ventricular and right ventricular volumes and ejection fraction with N-terminal pro-brain natriuretic peptide, and high-sensitive troponin was negative in all subjects.Based on our results, chronic right ventricular damage in elite endurance master athletes with lifelong high training volumes seems to be unlikely. Thus, the hypothesis of an exercise-induced arrhythmogenic right ventricular cardiomyopathy has to be questioned.
Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia
Authors: Jane E. Churpek, Khateriaa Pyrtel, Krishna-Latha Kanchi, Jin Shao, Daniel Koboldt, Christopher A. Miller, Dong Shen, Robert Fulton, Michelle O’Laughlin, Catrina Fronick, Iskra Pusic, Geoffrey L. Uy, Evan M. Braunstein, Mark Levis, Julie Ross, Kevin Elliott, Sharon Heath, Allan Jiang, Peter Westervelt, John F. DiPersio, Daniel C. Link, Matthew J. Walter, John Welch, Richard Wilson, Timothy J. Ley, Lucy A. Godley, Timothy A. Graubert
Journal: Blood (2015)
Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders
Authors: L Kofoed, J Kania, T Walsh, R M Atkinson
Journal: American Journal of Psychiatry (1986)

Thirty-two patients with coexisting substance abuse and other psychiatric disorders were treated in a unique outpatient pilot program that used techniques drawn from both psychiatric and substance abuse treatment. Eleven patients remained in treatment for 3 or more months, and seven completed a year or more of treatment. Severity of associated psychiatric illness did not affect retention in treatment. Drug-abusing patients and those with personality disorders dropped out quickly; patients with a history of reliable outpatient treatment involvement tended to remain in treatment. Treatment retention was associated with reduced hospital utilization. The authors suggest guidelines for management of patients with coexisting substance abuse and other psychiatric disorders.
Abstract PR10: HiClinc-1, a highly conserved Cancer-Testis lncRNA, regulates cell proliferation and tumor onset
Authors: Yasuyuki Hosono, John Prensner, Matthew Iyer, Yashar Niknafs, Rohit Malik, Anton Poliakov, Xuhong Cao, Jordan Shavit, Rohit Mehra, Weibin Zhou, Arul M. Chinnaiyan
Journal: Cancer Research (2016)

Abstract Long non-coding RNA (lncRNAs) have been shown to play an important role is a variety of cellular processes including cancer initiation and progression. Recently, we described a landscape of lncRNA using RNA-Seq data from more than 5000 cancer samples from 18 tissue types. Using novel bioinformatics based approach we were able to discover almost 50,000 novel transcripts. This list includes a subset of lncRNAs that contain ultra-conserved elements (UCE) termed “Highly Conserved Long Intergenic Non-Coding RNAs (HICLINCs)”. This provides a new opportunity for exploring the functions of highly conserved lncRNAs using genomic approaches. Among them, we focus on an lncRNA which we have termed HiClinc-1 (Highly Conserved Intergenic long-noncoding RNA-1), that is specifically expressed only in testis in benign tissue, and re-expressed in a broad range of cancer types. We described that HiClinc-1 exists in the messenger Ribonucleoprotein (mRNP) complex and binds to Insulin-Like Growth Factor 2 mRNA Binding Protein 1 (IGF2BP1), one of the component of mRNP complex in both human and zebrafish. HiClinc-1 regulates cell proliferation both in vivo and in vitro through the regulation of IGF2BP1's downstream target Insulin-Like Growth Factor 2 (IGF2). HiClinc-1 also enhanced tumor growth in mouse xenograft model. Notably, Human-HiClinc-1 injection in zebrafish embryos accelerated the onset and growth of NRAS K61-induced melanoma. Similarly, HiClinc-1 knockout background showed delayed onset of NRAS K61-induced melanoma. Taken together, we identified a novel Cancer-Testis lncRNA, which is highly conserved through human to zebrafish that can be a potential therapeutic target for cancer treatment. Citation Format: Yasuyuki Hosono, John Prensner, Matthew Iyer, Yashar Niknafs, Rohit Malik, Anton Poliakov, Xuhong Cao, Jordan Shavit, Rohit Mehra, Weibin Zhou, Arul M. Chinnaiyan. HiClinc-1, a highly conserved Cancer-Testis lncRNA, regulates cell proliferation and tumor onset. [abstract]. In: Proceedings of the AACR Special Conference on Noncoding RNAs and Cancer: Mechanisms to Medicines ; 2015 Dec 4-7; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2016;76(6 Suppl):Abstract nr PR10.
PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer
Authors: F. Sclafani, G. Brown, D. Cunningham, A. Wotherspoon, D. Tait, C. Peckitt, J. Evans, S. Yu, L. Sena Teixeira Mendes, J. Tabernero, B. Glimelius, A. Cervantes, J. Thomas, R. Begum, J. Oates, I. Chau
Journal: Annals of Oncology (2016)
FRI0149 Fifteen Years of Biological Treatment for Rheumatoid Arthritis: Data from the Italian Lorhen Registry
Authors: V. Grosso, R. Gorla, P. Sarzi-Puttini, F. Atzeni, R. Pellerito, E. Fusaro, G. Paolazzi, P.A. Rocchetta, E.G. Favalli, A. Marchesoni, R. Caporali
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> The role of biologic drugs (bDMARDs) in the treatment of rheumatoid arthritis (RA) has changed over time, due to increased availability, new evidences and different international recommendations. However, given their well-defined role in the treat-to-target approach, several authors found evidences of suboptimal adherence to it. <h3>Objectives</h3> The aim of this study is to review the baseline characteristics of an Italian multicentric observational cohort of patients with RA starting a bDMARDs from 1999 to 2015. <h3>Methods</h3> In the LORHEN registry, we identified all adult RA patients who were administered for the first time a bDMARD between 1 January 1999 and 1 January 2015. For analysis purpose, we divided the patients into three groups, according to the date of bDMARD administration: from 1999 to 2004 (Group 1), from 2005 to 2010 (Group 2) and from 2011 to May 2014 (Group 3). We performed between-groups comparisons of baseline demographics, disease characteristics and previous treatments with csDMARDs. <h3>Results</h3> We retrieved data from 2620 RA patients from eight different rheumatologic centers. Patients in Group 2 were younger but with a mean difference of less than 2 years with other groups. Patients in Group 3 had a statistically significant lower baseline DAS28 and HAQ compared with previous time groups. DAS28 at first switch was significantly lower in Group 3. Disease duration and time before first switch did not differed significantly between groups. <h3>Conclusions</h3> The disease activity at which rheumatologists opt for bDMARD treatment has progressively reduced over time, consistently with recommended tighter control of RA. However, most of the patients are given the first bDMARD only after years of csDMARDs, with an established disease, poorly fitting the principles of treat-to-target. Incomplete availability of bDMARDs over territory and economical concerns, in addition to incomplete adherence to international recommendations, might explain this fact. Differences in disease duration between real life patients treated with bDMARDs and those selected in the majority of clinical trials should be taken into account when applying inferences from RCTs to regular clinical practice. <h3>Disclosure of Interest</h3> None declared
MAPping the Wnt pathway to hepatocellular carcinoma recurrence
Authors: Béatrice Benoit, Christian Poüs
Journal: Gut (2016)

Early recurrence is a frequent cause of poor survival after hepatocellular carcinoma (HCC) resection. At the cell level, efforts to link HCC with the dysfunction of signalling pathways identified several alterations, especially in the Wnt/β-catenin pathway.1 Wnt signalling controls the balance between cell proliferation and differentiation and its regulation relies partly on subcellular compartmentalisation at the plasma membrane in late endosomes and/or on the cytoskeleton (see refs. 2 ,3 for reviews) (figure 1A).



Figure 1 
The Wnt/β-catenin pathway: regulation by subcellular compartmentalisation and links with the cell cycle through the involvement of Protein Regulator of Cytokinesis 1 (PRC1). (A) (1) The β-catenin destruction complex, which comprises adenomatous polyposis coli (APC), Axin, glycogen synthase kinase 3β (GSK3β) and casein kinase 1 (CK1), functions to phosphorylate free β-catenin, allowing its recognition by the E3 enzyme β-Transducin repeats-Containing Protein (β-TrCP) and its consecutive degradation by the proteasome. (2) The lipoprotein receptor-related protein (LRP)5/6 signalosome: Wnt agonist binding to its receptor complex (Frizzled+LRP5/6) allows LRP5/6 phosphorylation, Axin and Microtubule-Actin Crosslinking Factor 1 (MACF1) recruitment to the signalosome and then inactivation of GSK3β. (3) APC motorisation towards the microtubule plus ends allows its interaction with end-binding 1 (EB1) and mDia to stabilise microtubules at the migrating cell front. (4) Cytoplasmic PRC1 binds to microtubule bundles and interacts with the destruction complex to inactivate it. (5) Inactivation of the destruction complex leads to β-catenin nuclear entry and association with the T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription factor to promote gene expression. (6) Nuclear localisation of Axin, APC, Dishevelled (Dvl) and PRC1 modulates the Wnt/β-catenin signalling pathway. Nuclear APC competes with TCF/LEF for binding to β-catenin and favours its nuclear export. Nuclear Axin binds to the promoter region and competes with the binding of the β-catenin transcription complex on the promoter of target genes …
Strong signature of natural selection within an FHIT intron implicated in prostate cancer risk
Authors: Yan Ding, Garry Larson, Cathryn Lundberg, Guillermo Rivas, Theodore Krontiris
Journal: Cancer Research (2008)

AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

1903 

Previously, we identified a locus of prostate cancer susceptibility at D3S1234 within FHIT using a candidate gene-based linkage approach on brother pairs affected with prostate cancer. Subsequent association tests in Americans of European descent on 16 SNPs spanning approximately 381 kb surrounding D3S1234 revealed significant evidence of association for a single SNP within intron 5 of FHIT . Resequencing and genotyping within a 28.5 kb region surrounding this SNP further delineated association of prostate cancer risk to a 15 kb region. Several SNPs in sequences under evolutionary constraint within intron 5 of FHIT gene may function interactively to determine increased risk of prostate cancer in European Americans. In addition to highly conserved sequences, population studies (13 European Americans, 16 Yorubans, and 10 Japanese) revealed strong signatures of natural selection in human and primate populations. In conclusion, these results strongly support the involvement of the FHIT intronic region in an increased risk of prostate cancer. The current study also demonstrates the power of population genetics in mapping a common human disease.
Time to be honest regarding outcomes of ACL reconstructions: should we be quoting 55–65% success rates for high-level athletes?
Authors: Robert G McCormack, Mark R Hutchinson
Journal: British Journal of Sports Medicine (2016)

Five to ten years ago it was common for orthopaedic surgeons to assure their ACL injured patients that 90–95% of the time they would have a good to excellent result with surgical reconstruction. We suspect that such advice can still be heard in orthopaedic offices. However, recent studies evaluating return to play, recurrent or contralateral ACL injuries, and specific graft choices, have raised concern that the picture we were painting may have been too rosy.

Walden et al 1 present their outcomes of a prospective study on football (soccer) players regarding actual return to play rates. The authors followed 78 elite soccer clubs for 4 years and reported 140 complete ACL injuries (98% that underwent reconstruction). Surprisingly, prior to completing rehabilitation, five patients had reruptures and four required contralateral ACL surgery. At 3 years, 86% of patients were still playing football but only 65% were playing at …
Abstract P6-19-03: Overexpression of FOXM1 is a potential prognostic marker in male breast cancer
Authors: K Rahal, S Abdeljaoued, I Bettaieb, H Bouzaiene, O Adouni, S Miladi, A Goucha, H Bouaziz, R Makhlouf, M Hechiche, F Benna, H Boussen, A El May, A Gamoudi
Journal: Cancer Research (2016)

Abstract Background The Forkhead box M1 (FOXM1) transcription factor is known to play an important role in the development and progression of many cancer types including breast cancer. The important role of FOXM1 in cancer affirms its significance for clinical use and therapeutic intervention. Elevated expression of FOXM1 in female breast cancer correlates with undifferentiated tumor phenotype and negative clinical outcome. However, whether FOXM1 has any indication for prognosis in male breast cancer (MBC) patients is still unknown. The purpose of this study was to examine the expression levels of FOXM1 in MBC and to identify the relationship between FOXM1 expression and patient survival. Methodsl Immunohistochemical analysis for FOXM1 was performed in a total of 80 male breast cancer specimens, all with linked clinical outcome data. Kaplan-Meier method and Cox proportional hazards analysis were used to relate FOXM1 expression to clinicopathological variables and overall survival (OS). Results We observed high expression of the FOXM1 protein in 39 % of MBC samples (31/80). FOXM1 overexpression was significantly associated with higher histological grade (p=0.05), lymph node metastasis (p=0.04), tumor size (p=0.05), and estrogen receptor expression (p=0.04). Patients with FOXM1 expression had a significantly poorer overall survival than those without FOXM1 expression (p=0.02). Multivariate analyses indicated that FOXM1 positivity was an independent prognostic factor for OS (p=0.03). Conclusion These results show that FOXM1 may represent a novel MBC marker with prognostic significance that could be included into the limited marker panels for MBC. Citation Format: Rahal K, Abdeljaoued S, Bettaieb I, Bouzaiene H, Adouni O, Miladi S, Goucha A, Bouaziz H, Makhlouf R, Hechiche M, Benna F, Boussen H, El May A, Gamoudi A. Overexpression of FOXM1 is a potential prognostic marker in male breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-19-03.
Normal Range Of Bleeding Scores For The ISTH-BAT: Adult and Pediatric Data From The Merging Project
Authors: Malak Elbatarny, Shamim Mollah, Julie Grabell, Margaret L. Rand, Dewi S. Clark, Andreas Mauer, Pamela A. Christopherson, Robert R. Montgomery, Zimmerman Program Investigators, Barry S. Coller, Paula D. James
Journal: Blood (2013)
Reply to Umberto Capitanio, Paolo Dell’Oglio, Alessandro Larcher, and Francesco Montorsi's Reply to Kazutaka Saito's Words of Wisdom re: Nephron-sparing Techniques Independently Decrease the Risk of Cardiovascular Events Relative to Radical Nephrectomy in Patients with a T1a–T1b Renal Mass and Normal Preoperative Renal Function. Eur Urol. 2016;69:538
Authors: Kazutaka Saito
Journal: European Urology (2016)
Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colon rectal cancer: Results from the ITACa trial.
Authors: Andrea Casadei Gardini, Silvia Carloni, Emanuela Scarpi, Paolo Maltoni, Romolo Dorizzi, Alessandro Passardi, Giovanni Luca Frassineti, Paola Ulivi, Giorgia Marisi, Dino Amadori, Alessandro Lucchesi
Journal: Journal of Clinical Oncology (2015)

617 Background: Serum levels of interleukine-6 and C-reactive protein are significatively higher in patients with neoplastic conditions. Therefore, the determination of high-sensitivity C-reactive protein (hs-PCR) has been widely used as a surrogate marker for chronic elevation of circulating cytokines. Increased hs-CRP concentrations have been reported in many conditions, in particular in patients with cardiovascular diseases, obesity, diabetes, autoimmunity, inflammatory bowel diseases and cancer risk. Some authors, on the basis of these findings, have encouraged further studies to clarify the etiologic and prognostic role of the aforementioned test. Our study has been conducted in patients enrolled in the phase III prospective multicentric randomized “Italian Trial in Advanced Colorectal Cancer (ITACa),” in order to assess hs-CRP levels at diagnosis and their significance with respect to overall survival (OS) and progresion free survival. Methods: Peripheral blood samples from 133 consecutive patients were collected into EDTA tubes. The collection was obtained before the beginning of first line chemotherapy. The supernatant was immediately transfer into a cryovial and stored at –80°C. Samples were thawed and hs-CRP has been measured with Cobas c501 analyzer. Results: Levels of hs-CRP &gt;13.1 mg/L were associated with a worse median PFS, 8.9 months (95% CI 6.8-9.6) vs. 12.1 months (95% CI 9.3-14.9) in patients with levels &lt;13.1 mg/L (p&lt;0.0001). Similarly, levels &gt;13.1 mg/L were associated with worse median OS, 14.4 (95% CI 11.5-17.1) vs. 28.8 (95% CI 24.3-36.6) in patients with a concentration &lt;13.1 mg/L (p&lt;0.0001). In multivariate analysis, hs-PCR adjusted for baseline factors including age (&lt;70, ≥70 years), gender, ECOG perfomance status (0,1-2), tumor localization (rectum, colon), stage at diagnosis (I-III, IV), CT regimen (Folfiri, Folfox), KRAS status (wild type, mutant), site of metastases (liver, other metastases), was found to be independently associated with PFS and OS. Conclusions: Our study demonstrates the prognostic value of hs-CRP in patients with metastatic carcinoma of the colon and rectum.
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
Authors: Rick A. Nishimura, Catherine M. Otto, Robert O. Bonow, Blase A. Carabello, John P. Erwin, Robert A. Guyton, Patrick T. O’Gara, Carlos E. Ruiz, Nikolaos J. Skubas, Paul Sorajja, Thoralf M. Sundt, James D. Thomas
Journal: Circulation (2014)
Impact of Syrian Conflict on Its Children
Authors: M. J. Friedrich
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Inducible expression of antigen processing and antigen presentation molecules and cancer testis antigens in human prostate cancer
Authors: Erika Heninger, Timothy Krueger, Brian Johnson, Jamie Sperger, David Jarrard, Joshua Lang
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Defects in immune surveillance have been correlated with tumorigenesis and poor clinical outcomes in cancer patients. Given recent advances in vaccine therapies and checkpoint inhibition, therapeutic targeting of defective antigen processing may play a critical role in improving
Vestibular Neuritis
Authors: Robert W Baloh
Journal: New England Journal of Medicine (2003)

A 53-year-old man awoke in the morning with acute dizziness. He staggered to the bathroom, where he vomited repeatedly. When he was seen at the local emergency department 12 hours later, he had left-beating nystagmus in all positions of gaze but otherwise no focal neurologic findings. How should he be evaluated and treated?